Amelioration of ligamentum flavum hypertrophy using umbilical cord mesenchymal stromal cell-derived extracellular vesicles

• DOI: 10.1016/j.bioactmat.2022.03.042
• Publication Date: 2022-04-08T12:11:15Z
• Authors: Cheng Ma; Xin Qi; Yi-Fan Wei; Zhi Li; He-Long Zhang; He Li; Feng-Lei Yu; Ya-Nan Pu; Yong-Can Huang; Yong-Xin Ren
• Keywords: 0301 basic medicine; QH301-705.5; Umbilical cord mesenchymal stromal cells; Fibrosis; miR-221-3p; Article; Ligamentum flavum hypertrophy; 03 medical and health sciences; miR-146a-5p; TA401-492; Extracellular vesicle; Biology (General); Materials of engineering and construction. Mechanics of materials

Ligamentum flavum (LF) hypertrophy (LFH) has been recognised as one of the key contributors to lumbar spinal stenosis. Currently, no effective methods are available to ameliorate this hypertrophy. In this study, human umbilical cord mesenchymal stromal cell-derived extracellular vesicles (hUCMSC-EVs) were introduced for the first time as promising vehicles for drug delivery to treat LFH. The downregulation of miR-146a-5p and miR-221-3p expressions in human LF tissues negatively correlated with increased LF thickness. The hUCMSC-EVs enriched with these two miRNAs significantly suppressed LFH in vivo and notably ameliorated the progression of transforming growth factor β1(TGF-β1)-induced fibrosis in vitro after delivering these two miRNAs to mouse LF cells. The results further demonstrated that miR-146a-5p and miR-221-3p directly bonded to the 3'-UTR regions of SMAD4 mRNA, thereby inhibiting the TGF-β/SMAD4 signalling pathway. Therefore, this translational study determined the effectiveness of a hUCMSC-EVs-based approach for the treatment of LFH and revealed the critical target of miR-146a-5p and miR-221-3p. Our findings provide new insights into promising therapeutics using a hUCMSC-EVs-based delivery system for patients with lumbar spinal stenosis.